Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Brain Behav Immun. 2014 Sep 8;44:91–99. doi: 10.1016/j.bbi.2014.08.010

Fig. 1. Concomitant IB-MECA blocks the development of oxaliplatin-induced mechano-hypersensitivity.

Fig. 1

When compared to day (D) 0, administration of oxaliplatin (●) but not vehicle (○) led to a time-dependent development of mechano-allodynia (A) and mechano-hyperalgesia (B). The development of mechano-hypersensitivity was blocked by daily i.p. injections (D0–4) of the selective A3AR agonist IB-MECA (0.1 mg/kg/d, ▼). The Y-axis corresponding to paw withdrawal threshold (PWT) has been cropped for clarity. Results are expressed as mean ± SD; n=5 rats; two-way ANOVA with Bonferroni comparisons. *P<0.05 Vehicle or Oxaliplatin vs. D0; †P<0.05 Ox+IB-MECA vs. Oxaliplatin.